Targeted Therapies Forum 2022: In this video Dr. Isabel Preeshagul presents Dr. Fred R. Hirsch response to a patient who switched to Osimertinib from Erlotinib and saw disease progression.
We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech
For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.